How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,141 results for

Four Year Prognostic Index

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma (PubMed)

Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma We examined the overall survival rates of a national cohort to determine optimal treatments and prognostic factors for patients with metachronous second primary head and neck squamous cell carcinomas (mspHNSCCs) at different stages and sites. We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database. The patients were categorized into four groups based (...) HNSCC of <3 years were significant poor independent prognostic risk factors for overall survival. After adjustment, adjusted hazard ratios and 95% confidence intervals for the overall all-cause mortality risk at mspHNSCC clinical stages III and IV were 0.72 (0.40-1.82), 0.52 (0.35-0.75), and 0.32 (0.22-0.45) in Groups 2, 3, and 4, respectively. A Cox regression analysis indicated that a re-RT dose of ≥6000 cGy was an independent protective prognostic factor for treatment modalities. CCI ≥ 6, stage

Full Text available with Trip Pro

2016 Cancer medicine

82. A Novel Prognostic Score, Based on Preoperative Nutritional Status, Predicts Outcomes of Patients after Curative Resection for Gastric Cancer (PubMed)

A Novel Prognostic Score, Based on Preoperative Nutritional Status, Predicts Outcomes of Patients after Curative Resection for Gastric Cancer PURPOSE: We aimed to determine whether preoperative nutritional status (PNS) was a valuable predictor of outcome in patients with gastric cancer (GC). METHODS: We retrospectively evaluated 1320 patients with GC undergoing curative resection. The PNS score was constructed based on four objective and easily measurable criteria: prognostic nutritional index (...) (PNI) score 1, serum albumin <35 g/L, body mass index (BMI) <18.5 kg/m2, or preoperative weight loss ≥5% of body weight. The PNS score was 2 for patients who met three or four criteria, 1 for those who met one or two criteria, and 0 for those who didn't meet all of these criteria. RESULTS: The overall survival (OS) rates in patients with PNS scores 0, 1, and 2 were 59.1%, 42.4%, and 23.4%, respectively (P < 0.001). Multivariate analyses revealed the PNS was an independent predictor for OS (HR

Full Text available with Trip Pro

2016 Journal of Cancer

83. Nail involvement as a negative prognostic factor in biological therapy for psoriasis: a retrospective study. (PubMed)

Psoriasis Area Severity Index (PASI) 75 in patients with and without NP treated with biological therapy. The second end point was to evaluate the efficacy of biological therapy to improve NP.A total of 127 patients (88 men and 39 women) with moderate to severe Pso referring to our Service between 2007 and 2014 were included. Inclusion criteria were age ≥18 years and a 24 week treatment. The outcome variable was achievement of PASI 75 at 24 weeks with and without NP. All patients were treated (...) with topical therapy and one of four different biological treatments: adalimumab (44.09%), etanercept (18.11%), infliximab (13.39%) and ustekinumab (24.41%). Physical examinations were performed every 4 weeks, and at each visit, the clinician assessed the PASI and Nail Psoriasis Severity Index (NAPSI).At multivariate Cox regression analysis, a smaller proportion of patients with NP achieved PASI 75 at 24 weeks than patients without NP when adjusted for the epidemiological, clinical features and biological

2016 Journal of the European Academy of Dermatology and Venereology

84. Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. (PubMed)

at a tertiary centre were included. Technical success and clinical response after endovascular interventional therapy were documented. Predictors of survival were assessed with Cox-proportional model. A new score was derived from the factors significant on multivariate analysis and compared with Child-Turcotte-Pugh, model for end-stage liver disease (MELD), Rotterdam prognostic index (PI) and Budd-Chiari syndrome-transjugular intrahepatic portosystemic shunt ( BCS-TIPSS) PI.Three hundred and thirty-four (...) stenting). On Cox-proportional multivariate analysis, Child class C and response to intervention were independent predictors of outcome and used to derive the All India Institute of Medical Sciences (AIIMS) hepatic venous outflow tract obstruction score. The 5-year survival was 92% (95% CI, 81-97%) for score ≤3, 79% (95%CI, 63-88%) for score >3 and ≤4, and 39% (95% CI, 21-57%) for score >4. The performance of AIIMS hepatic venous outflow obstruction score was superior to other prognostic

Full Text available with Trip Pro

2016 Alimentary Pharmacology & Therapeutics

85. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. (PubMed)

, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68 (...) Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been

Full Text available with Trip Pro

2015 Journal of Clinical Oncology

86. A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension. (PubMed)

corresponding stratum, respectively. The mRASP (c-index = 0.727) demonstrated similar predictive power in contrast with the REVEAL risk assessment score (c-index = 0.715) in the prediction of one-year survival rate.The mRASP is an eligible risk assessment tool for the prognostic assessment of PAH. In contrast with the REVEAL score, it demonstrated similar predictive power and accuracy, with extra simplicity and convenience. (...) A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension. Risk assessment of pulmonary arterial hypertension (PAH) contributes to its management. Unfortunately, the existing risk assessment approaches are defective for clinicians to practice in daily clinical settings to some extent.We designed a modified Risk Assessment Score of PAH (mRASP) comprising four non-invasive variables which were World Health Organization functional class(WHO FC), 6-min

Full Text available with Trip Pro

2018 BMC pulmonary medicine

87. High one-year mortality following hospitalization for severe hypoglycemia among patients with diabetes mellitus: Findings of a retrospective cohort study at an acute tertiary care hospital in Singapore. (PubMed)

analysis.Three hundred and four patients (181 female and 123 male) were admitted with severe hypoglycemia in 2014, and the mean capillary blood glucose on admission was 2.3 ± 0.7 mmol/L. Sixty-three (20.7%) patients died within 1-year post-discharge from the hospital. Compared with patients who survived 1-year post-discharge from the hospital, non-survivors were older (69.3 ± 11.0 vs 75.5 ± 11.2 years, p < .001), had longer lengths of stay (LOS) (5.0 ± 7.4 vs 9.0 ± 12.8 days, p = .02), and had a higher (...) Charlson Comorbidity Index (CCI) (4.1 ± 1.9 vs 5.9 ± 2.4, p < .001). Factors associated with increased 1-year mortality risk were age (odds ratio [OR] = 1.06; 95% confidence interval [CI] = 1.03-1.09, p < .01), LOS in hospital (OR = 1.01; 95% CI = 1.01-1.08, p < .01), and CCI (OR = 1.51; 95% CI = 1.31-1.75, p < .01), respectively.Older diabetes patients with more comorbidities and longer LOS were at increased risk of dying within a year of discharge after hospitalization with severe hypoglycemia

2018 Current medical research and opinion

88. Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery

data: The clinical data came from a selection of known, relevant studies, including two main sources. The risk of events while on the waiting list was from a large prospective database; the Swedish Coronary Angiography and Angioplasty Registry, which included 9,935 patients with stable angina, who were followed-up for 3.8 years after their CABG. The prognostic effect of biomarkers, which was the key clinical input, was estimated by undertaking a systematic review of the literature in the MEDLINE (...) Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery Henriksson M, Palmer S

Full Text available with Trip Pro

2010 NHS Economic Evaluation Database.

89. Evaluation of the Use of Electronic Health Data to Classify Four-Year Mortality Risk for Older Adults Undergoing Screening Colonoscopies (PubMed)

to physicians in ways that better align screening recommendations with patients who are more likely to live long enough to benefit from early detection. We have evaluated the performance of an existing prognostic index for 4-year mortality using data readily available in the electronic health record (EHR), and investigated the effect of the index in retrospective cohorts of adults age 65 and older undergoing screening colonoscopy. Risk scores in this adaptation of a four-year prognostic index were found (...) Evaluation of the Use of Electronic Health Data to Classify Four-Year Mortality Risk for Older Adults Undergoing Screening Colonoscopies Current cancer screening recommendations often apply coarse age cutoffs for screening requirements without regard to predicted life expectancy. Using these cutoffs, healthier older patients may be under-screened, and sicker younger patients may be screened too often. Mortality risk classification using EHR data could be used to tailor screening reminders

Full Text available with Trip Pro

2011 AMIA Annual Symposium Proceedings

90. Post-Operative Management of Legg-Calve-Perthes Disease In children aged 3 to 12 years

with woven bone, which then remodels to trabecular bone. The flattening of the femoral head may improve. This stage ends when the entire head has reossified and is typically the longest of the four, with a mean duration of 51 months (Herring 2001 [5b]). Evidence-Based Care Guideline for Management of Legg-Calve-Perthes Disease Stages 1 to 4 Status-post Surgical Intervention in Children aged 3 to 12 years Guideline 41 Copyright © 2013 Cincinnati Children's Hospital Medical Center; all rights reserved (...) Post-Operative Management of Legg-Calve-Perthes Disease In children aged 3 to 12 years Evidence-Based Care Guideline for Management of Legg-Calve-Perthes Disease Stages 1 to 4 Status-post Surgical Intervention in Children aged 3 to 12 years Guideline 41 Copyright © 2013 Cincinnati Children's Hospital Medical Center; all rights reserved. Page 1 James M. Anderson Center for Health Systems Excellence Evidence-Based Care Guideline Post-Operative Management of Legg-Calve-Perthes Disease In children

2013 Cincinnati Children's Hospital Medical Center

91. Four anterior STEMIs: acute and reperfused vs. won't reperfuse, subacute and reperfused vs. not reperfused

Four anterior STEMIs: acute and reperfused vs. won't reperfuse, subacute and reperfused vs. not reperfused Dr. Smith's ECG Blog: Four anterior STEMIs: acute and reperfused vs. won't reperfuse, subacute and reperfused vs. not reperfused Wednesday, October 26, 2011 These 4 recent cases illustrate acute and subacute MI with reperfusion and absence of reperfusion (or failed reperfusion). QS-waves and depth of T-wave inversion are very helpful in determining the duration of injury (the "acuteness (...) immediately after reperfusion , illustrating how hyperacute T-waves are present BOTH shortly after occlusion (when ST segments are on the way up) and shortly after reperfusion (when ST segments are on the way down). 4. A 51 year old male with h/o stent presented with 30 minutes of chest pain: Obvious anterolateral very acute STEMI with hyperacute T-waves He went for immediate PCI, with successful reperfusion of a 100% occluded proximal LAD, and a door to balloon time of 35 minutes . This was recorded 2.5

2011 Dr Smith's ECG Blog

92. Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN™ I first-in-human study using a multi-electrode ablation system. (PubMed)

Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN™ I first-in-human study using a multi-electrode ablation system. Long term safety and efficacy data of multi-electrode ablation system for renal denervation (RDN) in patients with drug resistant hypertension (dRHT) are limited.We studied 46 patients (age: 60 ± 10 years, 4.7 ± 1.0 antihypertensive drugs) with drug resistant hypertension (dRHT). Reduction in office BP at 24 months from baseline (...) was -29/-13 mmHg, while the reduction in 24-hour ambulatory BP and in home BP at 24 months were -13/-7 mmHg and -11/-6 mmHg respectively (p<0.05 for all). A correlation analysis revealed that baseline office and ambulatory BP were related to the extent of office and ambulatory BP drop. Apart from higher body mass index (33.3 ± 4.7 vs 29.5 ± 6.2 kg/m(2), p<0.05), there were no differences in patients that were RDN responders defined as ≥10 mmHg decrease (74%, n=34) compared to non-responders. Stepwise

2015 International journal of cardiology

93. Four layer bandage compared with short stretch bandage for venous leg ulcers: systematic review and meta-analysis of randomised controlled trials with data from individual patients

controlled trials with data from individual patients O'Meara S, Tierney J, Cullum N, Bland J M, Franks P J, Mole T, Scriven M CRD summary The authors of this review of individual patient data concluded that the four layer bandage increases the chance of healing by approximately 30%, when independent prognostic characteristics are taken into account, and benefits are consistent across different prognostic profiles. This was a well-conducted and reported review and the conclusions are likely to be reliable (...) of eligible trials were scanned, and collaborating trialists were consulted to provide details of any further studies. Study selection Randomised controlled trials (RCTs) comparing the four layer bandage with the short stretch bandage for treating participants with venous leg ulcers (defined as ankle brachial pressure index (ABPI) ≥0.8 plus clinical history) were eligible for inclusion in the review. The primary outcome of interest was time to healing (days). Secondary outcomes included: time to ulcer

2009 DARE.

94. Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma. (PubMed)

, vincristine, prednisone given every 14 d) in previously untreated elderly patients with diffuse large B-cell lymphoma (DLBCL). We included 51 patients (median age 66 years, range 60-76). Median dose intensity did not differ between the group of 24 patients receiving four doses of unpegylated filgrastim of each cycle (87·5%) and the group of 27 patients receiving pegylated filgrastim once per cycle on day 2 (89·4%) (P = 0·9). There was also no difference in the frequency of adverse events, such as episodes (...) of neutropenic fever and unplanned hospitalizations. Patient characteristics that negatively influenced dose intensity were reduced performance status, advanced stage disease and poor-risk International Prognostic Index, with Eastern Cooperative Oncology Group performance status ≥2 being the most significant factor. In conclusion, a limited support with 4 d of filgrastim appears to be equivalent to pegylated filgrastim administered once per cycle, and appears to be sufficient to maintain dose-intensity

Full Text available with Trip Pro

2015 British journal of haematology Controlled trial quality: uncertain

95. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit (PubMed)

Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit To investigate the prognostic value of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in patients who received transplantation admitted to the intensive care unit (ICU).We investigated the association of HCT-CI with inpatient mortality and overall survival (OS) among 377 (...) patients who were admitted to the ICU within 100 days of allogeneic stem-cell transplantation (ASCT) at our institution. HCT-CI scores were collapsed into four groups and were evaluated in univariate and multivariate analyses using logistic regression and Cox proportional hazards models.The most common pretransplantation comorbidities were pulmonary and cardiac diseases, and respiratory failure was the primary reason for ICU admission. We observed a strong trend for higher inpatient mortality

Full Text available with Trip Pro

2013 EvidenceUpdates

96. Pre-fracture quality of life predicts 1-year survival in elderly patients with hip fracture-development of a new scoring system. (PubMed)

Pre-fracture quality of life predicts 1-year survival in elderly patients with hip fracture-development of a new scoring system. Hip fractures are common in elderly people. Despite great progress in surgical care, the outcome of patients with hip fracture remains disappointing. This study determined four prognostic factors (lower ASA score, higher pre-fracture EQ-5D index, higher MMSE score, and female gender) to predict 1-year survival in patients with hip fracture.This study determined (...) -year follow-up. In multivariate regression analysis, independent predictors of 1-year survival were lower ASA score, higher pre-fracture EQ-5D index, higher MMSE score, and female gender. The different variables were weighted according to their β-coefficient to build the prognostic score, which ranged from 0 to 10 points. The ROC curve for 1-year mortality after hip fracture showed an area under the curve of 0.74 (R (2) = 0.272; 95 % CI 0.68-0.79; p < 0.001).With only four instruments, the new

2016 Osteoporosis International

97. Three year functional changes and long-term mortality hazard in community-dwelling older men. (PubMed)

≥71years at wave 2 (baseline of the present analysis), living in the semi-rural community of Merelbeke (Belgium). Physical function assessments included the Short Form-36 (SF-36) Physical Function Index, Grip strength, Chair rising, and Timed Up and Go. Changes over a 3-year time were calculated using data obtained at four annual visits.After a 15-year follow-up, 149 men (87%) died. Median survival time was 8.2 (4.2-12.4) years. Physical function assessed at a single time point (at wave 2 or wave 5 (...) Three year functional changes and long-term mortality hazard in community-dwelling older men. Low levels of physical function have been associated with higher mortality hazard in older persons. However, few studies have investigated the association between functional changes and subsequent mortality. This study aimed to examine whether 3-year functional changes independently predict subsequent all-cause mortality.This population-based cohort study included 171 community-dwelling men aged

2016 European journal of internal medicine

98. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N (PubMed)

by myeloablative radiochemotherapy and ASCT (control group), or six courses of alternating R-CHOP or R-DHAP (rituximab plus dexamethasone, high-dose cytarabine, and cisplatin) followed by a high-dose cytarabine-containing conditioning regimen and ASCT (cytarabine group). Patients were stratified by study group and international prognostic index. The primary outcome was time to treatment failure from randomisation to stable disease after at least four induction cycles, progression, or death from any cause (...) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell

2016 Lancet (London, England) Controlled trial quality: predicted high

99. Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer

of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer Study Start Date : January 2014 Actual Primary Completion Date : June 2015 Actual Study Completion Date : June 2015 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment BCI Assay Results The Breast Cancer Index (BCI) is a novel gene expression-based prognostic predictor for ER (...) of the following criteria in order to be considered for enrollment: Histologically confirmed ER positive, stage I-III breast cancer who have been treated with curative intent and completed at least four years of adjuvant endocrine therapy. Life expectancy ≥ 5 years. Must be able to provide informed consent. Willing to consider continuation of endocrine therapy beyond 5 years. Exclusion Criteria: A patient must not be enrolled if any contraindication exists for extended adjuvant endocrine therapy as identified

2014 Clinical Trials

100. Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease

Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02474329 Recruitment Status : Completed First Posted : June 17, 2015 Last Update Posted : October 12, 2017 Sponsor: Radboud University Collaborators: Michael J. Fox

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>